What was the primary driver of the revenue growth in the quarter?

Revenue growth was driven by a combination of factors including increased sales of safety-engineered products, strong performance in diagnostic tests (especially respiratory and flu), growth in immunocytometry instruments and reagents within the Biosciences segment, and a favorable foreign currency impact on international revenues.

Can you explain the impact of the Blood Glucose Monitoring (BGM) product issues?

BD incurred a pre-tax charge of $45 million in the quarter related to its BGM products. This included a reserve for a voluntary product recall of certain test strips, the write-off of affected inventory, and the discontinuation of support for the BD Latitude system in the U.S., leading to write-offs of related meters and assets. This charge negatively impacted the Medical segment's operating income and reduced the overall gross profit margin by 370 basis points.

How is the company managing its debt and capital structure?

BD demonstrated strong financial health by reducing its debt-to-capitalization ratio to 27.2% from 30.4% in the previous quarter. This was supported by substantial net cash provided by operating activities ($213 million) and strategic financing activities including debt repayment and share repurchases.

What is the outlook for safety-engineered devices?

The company expects continued growth in its U.S. safety-engineered device sales, projecting a range of 10% to 15% annual growth over the next several years due to market transition, innovation, and product line expansion.

BDX 10-Q Quarterly Report Q1 FY2004 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported its third quarter results for fiscal year 2003, ending December 31, 2003. The company demonstrated solid revenue growth, with a 14.1% increase year-over-year to $1.2 billion, driven by strong performance across its Medical, Diagnostics, and Biosciences segments, with international revenues showing particularly robust growth. Net income rose to $125.4 million from $113.6 million in the prior year period, leading to improved diluted earnings per share of $0.48. Despite the overall positive financial results, the company faced a significant charge related to its Blood Glucose Monitoring (BGM) products, including a product recall and inventory write-offs, which negatively impacted the Medical segment's operating income and reduced gross profit margin by 3.7%. However, strategic investments in safety-engineered devices and increased sales in areas like diagnostic tests and immunocytometry instruments contributed to the positive top-line performance. The company also continued its commitment to returning capital to shareholders through share repurchases and an increased dividend.

Key Highlights

1Total revenues increased by 14.1% to $1.2 billion for the three months ended December 31, 2003, compared to the prior year period.
2Net income grew by 10.4% to $125.4 million, resulting in diluted earnings per share of $0.48, up from $0.43 in the prior year.
3The Medical segment experienced revenue growth of 9.7%, despite a $45 million charge impacting operating income due to issues with Blood Glucose Monitoring (BGM) products.
4The Diagnostics segment showed strong revenue growth of 20.9%, driven by diagnostic tests and the BD ProbeTec ET system.
5The Biosciences segment reported a revenue increase of 15.7%, boosted by sales of the BD FACSAria cell sorter and reagents.
6International revenues grew by a significant 23.0% (9.0% on a constant currency basis), indicating strong global demand.
7The company repurchased 1.87 million shares of common stock during the quarter and increased its quarterly dividend to $0.15 per share from $0.10.
8Debt-to-capitalization ratio improved to 27.2% from 30.4%, reflecting strong cash flow from operations and debt management.

BECTON DICKINSON & CO Quarterly Report for Q1 Ended Dec 31, 2003

Summary

Key Highlights

Frequently Asked Questions